Activity of AT-2266 compared with those of norfloxacin, pipemidic acid, nalidixic acid, and gentamicin against various experimental infections in mice.
AT-2266 (1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1, 8-naphthyridine-3-carboxylic acid) showed marked activity in vivo when administered orally to mice bearing systemic, pulmonary, dermal, or urinary tract infections due to variety of organisms. The activity of AT-2266 was uniformly higher than those of norfloxacin, pipemidic acid, and nalidixic acid against all of the infections. The activity of AT-2266 administered orally was almost comparable to that of gentamicin administered subcutaneously against urinary tract infections due to gram-negative organisms but was generally lower against other infections. AT-2266 exhibited significant activity against infections due to gentamicin-resistant and nalidixic acid-resistant organisms.
D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D015365:Enoxacin; D005839:Gentamicins / Q000627:therapeutic use; D008297:Male; D051379:Mice; D009268:Nalidixic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D009287:Naphthyridines / Q000627:therapeutic use*; D009643:Norfloxacin; D010876:Pipemidic Acid / Q000627:therapeutic use
D000890:Anti-Infective Agents; D005839:Gentamicins; D009287:Naphthyridines; D015365:Enoxacin; D009268:Nalidixic Acid; D010876:Pipemidic Acid; D009643:Norfloxacin